Physician profile
Stuart B Kipper
NPI 1114956570
$941.20
in general payments reported to CMS, 2019-2025
14 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.14 · 2020: $53.97 · 2021: $109 · 2022: $97.16 · 2023: $174 · 2024: $179 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $312.15 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $120.20 | 2023-2024 | Gemtesa |
| Lilly USA, LLC | $79.24 | 2021-2022 | |
| Depuy Synthes Sales INC. | $74.97 | 2022-2025 | Orthovisc |
| Novo Nordisk INC | $72.50 | 2023-2024 | Ozempic, Rybelsus |
| Antares Pharma, INC. | $70.63 | 2019-2020 | |
| Allergan, INC. | $50.86 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $43.27 | 2024-2025 | Rexulti |
| Amgen INC. | $29.63 | 2019-2022 | |
| Astellas Pharma US INC | $22.32 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.39 | 2025 | Relistor |
| Teva Pharmaceuticals USA, INC. | $16.42 | 2025 | Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $13.96 | 2022 | |
| Pfizer INC. | $13.66 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Kipper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.